医学部

Naoki Ohmiya

  (大宮 直木)

Profile Information

Affiliation
School of Medicine Faculty of Medicine, Department of Advanced Endoscopy (formerly Department of Gastroenterology), Fujita Health University
Degree
博士(医学)

J-GLOBAL ID
200901011108502975
researchmap Member ID
6000005568

患者さんの立場にたって、安全かつ最高の医療を提供できるよう努力します。

Awards

 5

Papers

 291
  • Naoki Ohmiya, Masahiko Nakamura, Makoto Urano, Hisanori Muto, Satoshi Yamamoto, Takashi Kobayashi, Senju Hashimoto
    Gut, Nov 10, 2026  
  • Shinichiro Shinzaki, Katsuyoshi Matsuoka, Toshimitsu Fujii, Ryuichi Okamoto, Akihiro Yamada, Reiko Kunisaki, Minoru Matsuura, Kenji Watanabe, Hisashi Shiga, Noritaka Takatsu, Shigeki Bamba, Yohei Mikami, Takayuki Yamamoto, Takahiro Shimoyama, Satoshi Motoya, Takehiro Torisu, Taku Kobayashi, Naoki Ohmiya, Masayuki Saruta, Koichiro Matsuda, Takayuki Matsumoto, Hiroshi Nakase, Atsuo Maemoto, Shinichi Yoshigoe, Hiroaki Tsuchiya, Akiko Hori-Nishi, Tadakazu Hisamatsu
    Journal of Crohn's & colitis, 20(11), Nov 7, 2026  
    BACKGROUND AND AIMS: Multiple advanced therapies are available for the treatment of Crohn's disease (CD). Treatment patterns in newly diagnosed patients and the factors associated with persistence remain unclear. We present interim results of the iCREST-CD registry describing treatment patterns and persistence with advanced therapies. METHODS: Patients aged ≥16 years with newly diagnosed CD and who had no prior exposure to advanced therapies were enrolled. Persistence of advanced therapies was estimated using Kaplan-Meier analyses, and associated factors were identified using multivariable Cox proportional hazards models. Persistence was also compared between patients who initiated therapy early or later after diagnosis. RESULTS: Of 672 patients (68.2% male; mean age 29.4 ± 13.1 years), 498 (74.1%) initiated advanced therapy: infliximab (IFX; 121), adalimumab (ADA; 244), ustekinumab (UST; 107), or vedolizumab (VDZ; 26). Advanced therapy was initiated within 1 year of diagnosis in 404 (60.1%). The 36-month treatment persistence rates for IFX, ADA, UST, and VDZ were 77.5%, 75.7%, 79.8%, and 49.0%, respectively. After propensity score adjustment using inverse probability of treatment weighting, the early initiation was associated with greater persistence than delayed initiation, although the difference did not reach statistical significance (hazard ratio, 0.61; 95% confidence interval, 0.35-1.09; P = .067). CONCLUSIONS: A high prevalence of early advanced therapy use and a high level of persistence with first-line advanced therapy were identified in this national cohort. Early initiation was associated with greater treatment persistence than delayed initiation, suggesting the potential clinical relevance of earlier advanced therapy use in routine practice. These findings require confirmation in other prospective studies aiming to evaluate early intervention strategies. REGISTRATION: The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (umin.ac.jp/ctr Identifier: UMIN000032237) prior to initiation.
  • Naoki Ohmiya, Kiichi Otani, Kentaro Murashima, Masahito Shimizu
    Gastrointestinal endoscopy, Sep 9, 2026  
  • Masafumi Kitamura, Tomonori Yano, Shiro Oka, Takehiro Torisu, Akio Shiomi, Kinichi Hotta, Fumio Ishida, Shin-Ei Kudo, Takeshi Yamada, Keigo Mitsui, Masazumi Okajima, Toshio Uraoka, Hiroaki Nozawa, Koichi Kurahara, Hiroaki Ikematsu, Masaaki Ito, Keiichi Takahashi, Shoichi Saito, Masashi Ueno, Shigeki Yamaguchi, Yasumori Fukai, Toshio Kuwai, Shinji Nagata, Yoichi Ajioka, Tomohiro Kato, Yoji Takeuchi, Yojiro Hashiguchi, Naoki Ohmiya, Tomoki Yamano, Michio Itabashi, Eiji Sunami, Eigo Otsuji, Yukihide Kanemitsu, Hiroyuki Takamaru, Takayuki Matsumoto, Tamotsu Sugai, Masaya Kawai, Takashi Yao, Tetsuji Takayama, Eiji Shinto, Kazuo Ohtsuka, Yusuke Kinugasa, Kenichi Sugihara, Motohiro Esaki, Takeshi Kato, Kazutomo Togashi, Yoshito Akagi, Hiroshi Kashida, Takahiro Horimatsu, Yusuke Saitoh, Kazutaka Yamada, Keiji Koda, Madoka Hamada, Koji Komori, Akira Toyoshima, Shinji Tanaka, Hironori Yamamoto
    Journal of gastroenterology, 61(6) 732-740, Jun, 2026  
    BACKGROUND: Primary small intestinal lymphoma (PSIL) is a rare disease, and its clinical characteristics and prognostic factors remain insufficiently defined because of limited large-scale data. METHODS: We conducted a nationwide multicenter retrospective study of 686 patients diagnosed with PSIL between January 2008 and December 2017 at 44 institutions in Japan. Clinical characteristics, histological subtypes, and overall survival were analyzed. RESULTS: B-cell lymphoma was the predominant immunophenotype (n = 623, 91%), whereas T-cell lymphoma was uncommon (n = 50, 7%). Diffuse large B-cell lymphoma (DLBCL) was the most frequent histological subtype (n = 330, 48%), followed by follicular lymphoma (FL) (n = 224, 33%). Compared with other B-cell lymphomas, FL was more common in women and more frequently involved the jejunum (P < 0.001). The 5-year overall survival rate was significantly higher in patients with B-cell lymphoma than in those with T-cell lymphoma (81% vs. 23%, P < 0.001). Multivariate Cox regression analysis identified age > 60 years and T-cell lymphoma as independent adverse prognostic factors, whereas FL was an independent predictor of favorable overall survival. CONCLUSIONS: This nationwide multicenter analysis delineates the clinicopathological features and survival outcomes of PSIL in Japan. FL represents the second most common subtype after DLBCL and is associated with a favorable prognosis among PSIL subtypes.
  • YUMI MASHIMO, Hiroyuki Takamaru, Tomohiro Kadota, Tomonori Yano, Kazuki Sumiyama, Mamoru Ito, Naoki Ohmiya, Noriyuki Horiguchi, Shomei Ryozawa, Koichi Furukawa, Ken Ohata, Yohei Minato, Susumu Banjoya, Hiroshi Kashida, Yoriaki Komeda, Saki Yoshida, Koichi Nonaka, Hiroshi Matsunaga, Hideki Ishikawa, Kenichi Yoshimura, Seiichiro Abe, Yutaka Saito, Hisao Tajiri
    Gastrointestinal Endoscopy, 103(5) S-2512, May, 2026  

Misc.

 1339

Books and Other Publications

 51

Presentations

 456

Research Projects

 31

Media Coverage

 32